Post hoc analysis of VANISH (171 participants with early-stage hypertrophic cardiomyopathy): elevated BMI was associated with worse exercise capacity, more adverse remodelling and new late gadolinium enhancement (OR 3.6); BMI did not modify valsartan's effect.
Secondary analysisn = 171
Ostrominski et al. Body Mass Index, Valsartan, and Myocardial Remodeling in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial